NCT06855264View on ClinicalTrials.gov

A Cardiac Liability Study of Varegacestat in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

February 24, 2025

Primary Completion Date

April 8, 2025

Study Completion Date

May 6, 2025

Conditions
Healthy Volunteer
Interventions
DRUG

varegacestat

Single oral dose of varegacestat

DRUG

Placebo

Single oral dose of placebo

DRUG

Moxifloxacin 400 mg

Single oral dose of moxifloxacin

Trial Locations (1)

85289

Celerion, Tempe

Sponsors

Lead Sponsor

Immunome, Inc.
All Listed Sponsors
lead

Immunome, Inc.

INDUSTRY